{"id":"5c20f039-3ee2-5fa4-a992-d140a35397d5","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-adding-antibody-restores-it","predicate":"enables","statement":"In two single-patient studies, one in a patient with metastatic colorectal cancer who received BTH1677 combined with the tumour targeting antibody cetuximab and a second in a patient with metastatic neuroendocrine tumour who received BTH1677 combined with the immune checkpoint inhibitor pembrolizumab, the patients had low serum titres of antibodies against beta-glucan and low innate immune effector functionality induced by BTH1677, and addition of intravenous immunoglobulins restored innate immune activity of BTH1677 and induced clinically meaningful anti-tumoural activity with long-term disease control.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"8e211cc9-4c74-55ad-843a-db5d78c399ad","mechanism_event_label":"Two patients who lacked the antibody were given antibody, and the drug started working.","subject":{"id":"33c1a9f5-d7ed-5008-a8f9-03c06d4f3649","slug":"intravenous-immunoglobulin","display_name":"Intravenous immunoglobulin","entity_type_key":"protein"},"object":{"id":"a04b52d4-0af9-594a-bbda-51a16406d235","slug":"imprime-pgg","display_name":"Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"drug"},"evidence_count":1,"mechanism_event":{"id":"8e211cc9-4c74-55ad-843a-db5d78c399ad","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-adding-antibody-restores-it-event","event_type":"observed_intervention","label":"Two patients who lacked the antibody were given antibody, and the drug started working.","description":"In two single-patient studies, one in a patient with metastatic colorectal cancer who received BTH1677 combined with the tumour targeting antibody cetuximab and a second in a patient with metastatic neuroendocrine tumour who received BTH1677 combined with the immune checkpoint inhibitor pembrolizumab, the patients had low serum titres of antibodies against beta-glucan and low innate immune effector functionality induced by BTH1677, and addition of intravenous immunoglobulins restored innate immune activity of BTH1677 and induced clinically meaningful anti-tumoural activity with long-term disease control.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"afe6f619-e984-533b-b63a-83b4e77aab4f","slug":"anti-beta-glucan-antibodies","display_name":"Naturally occurring anti-beta-glucan IgG antibodies","entity_type_key":"protein"},"role":"supplied_requirement","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"a04b52d4-0af9-594a-bbda-51a16406d235","slug":"imprime-pgg","display_name":"Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"drug"},"role":"rescued_therapy","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"e1d483e1-8ffb-573f-a06e-10a7c76927bc","slug":"pembrolizumab","display_name":"Pembrolizumab","entity_type_key":"drug"},"role":"coadministered_drug","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"33c1a9f5-d7ed-5008-a8f9-03c06d4f3649","slug":"intravenous-immunoglobulin","display_name":"Intravenous immunoglobulin","entity_type_key":"protein"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/glucan-research/32132045.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7dea757c889af10839a38a317d704760e7e15798bc15a5da3a1323ec4143cf42\", \"start_char\": 0, \"end_char\": 1102, \"text_sha256\": \"7dea757c889af10839a38a317d704760e7e15798bc15a5da3a1323ec4143cf42\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Two single-patient reports of immunoglobulin infusion in patients with low anti-glucan antibody","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"BTH1677 with cetuximab or with pembrolizumab, plus intravenous immunoglobulin","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Two patients. This is an anecdotal test of a mechanism, not evidence of treatment benefit, and no control condition exists for the tumour outcome.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.","comparator":null,"unit":null,"notes":"","entity":{"slug":"beta-glucan","display_name":"Beta-glucan","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Two patients who lacked the antibody were given antibody, and the drug started working.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[bg-p32132045] Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan. (2020). https://pubmed.ncbi.nlm.nih.gov/32132045/ DOI: 10.21873/anticanres.14090","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Peripheral blood and tumour","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"573a745e-6ef9-5f2f-aa7b-fefe8065dd75","evidence_kind":"source_excerpt","locator":"Lines 294-305","start_line":294,"end_line":305,"excerpt":"### bg-adding-antibody-restores-it\nIn two single-patient studies, one in a patient with metastatic colorectal cancer who received BTH1677 combined with the tumour targeting antibody cetuximab and a second in a patient with metastatic neuroendocrine tumour who received BTH1677 combined with the immune checkpoint inhibitor pembrolizumab, the patients had low serum titres of antibodies against beta-glucan and low innate immune effector functionality induced by BTH1677, and addition of intravenous immunoglobulins restored innate immune activity of BTH1677 and induced clinically meaningful anti-tumoural activity with long-term disease control.\nCondition category: biomarker_context\nnutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.\nplain_language: Two patients who lacked the antibody were given antibody, and the drug started working.\norganism: Human\ntissue_or_cell_type: Peripheral blood and tumour\nexperimental_model: Two single-patient reports of immunoglobulin infusion in patients with low anti-glucan antibody\nlimitations: Two patients. This is an anecdotal test of a mechanism, not evidence of treatment benefit, and no control condition exists for the tumour outcome.\nexposure: BTH1677 with cetuximab or with pembrolizumab, plus intravenous immunoglobulin\nevidence_span: {\"source_cache\": \"artifacts/glucan-research/32132045.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7dea757c889af10839a38a317d704760e7e15798bc15a5da3a1323ec4143cf42\", \"start_char\": 0, \"end_char\": 1102, \"text_sha256\": \"7dea757c889af10839a38a317d704760e7e15798bc15a5da3a1323ec4143cf42\"}\n[bg-p32132045] Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan. (2020). https://pubmed.ncbi.nlm.nih.gov/32132045/ DOI: 10.21873/anticanres.14090","model_system":"Two single-patient reports of immunoglobulin infusion in patients with low anti-glucan antibody","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [bg-p32132045] Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan. (2020). https://pubmed.ncbi.nlm.nih.gov/32132045/ DOI: 10.21873/anticanres.14090","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"74dc223d-8289-57bf-a731-d220fa017c1e","stable_key":"import-10629adf-a816-5b7b-82db-a76bfbb946f2","title":"Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"7c62f2d2f8d99b650e6dc26a505b0f053ae1c8bdb38099d4dfc0771f65287461","revision_id":"a53bb794-0a4b-525d-9cf7-22b46a5403b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}